Atrial Fibrillation and Diabetes Mellitus: the Control of Thromboembolic Risk

Обрезан, А. Г.; Куликов, Н. В.

doi:10.18087/cardio.2020.7.n1146

Cited by 5 publications

(1 citation statement)

References 51 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…По результатам анализа зарубежных и российских исследований возможно говорить о том, что мультипликативный эффект развития негативных клинических исходов у пациентов с ФП ассоциирован со многими факторами: с возрастом, длительностью анамнеза сердечно-сосудистых событий, наличием АГ, ХСН, сахарного диабета, ХБП, каждый из которых увеличивает риски тромбоэмболических событий при ФП [17][18][19]. В связи с этим необходимо не только научное, но и клиническое понимание влияния каждого фактора в отдельности и их совокупности на тяжесть состояния, возможность развития тромбоэмболических осложнений, в том числе, с летальными исходами, а также коррекцию этих факторов риска в аспекте антикоагулянтной профилактической стратегии [6].…”

Section: мультипликативные эффекты и профилактическая стратегия ранне...unclassified

The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation

Zolotovskaya

Sabanova

Давыдкин

2021

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Anticoagulant therapy of patients with atrial fibrillation is an integral part of their treatment strategy. The high risk of developing a cardioembolic stroke and the high comorbidity of this group of patients necessitates a comprehensive approach to treatment, taking into account all available risk factors. Atrial fibrillation is often asymptomatic and timely detection of these patients can be one of the most important tasks in the complex of measures aimed at protecting patients from stroke. The European Society of Cardiology's 2020 guidelines suggest the use of a CC to ABC patient management strategy. This strategy involves a number of measures aimed at managing atrial fibrillation, including confirming the diagnosis, determining the characteristics of atrial fibrillation and treatment tactics. One of the points of this strategy is the control of comorbidities and risk factors for cardiovascular diseases. To date, rivaroxaban has a number of convincing and reliable data on a high profile of efficacy and safety in the treatment of comorbid patients who not only have a high risk of stroke, but also need protection from coronary events and decreased renal filtration function. These data are confirmed by both the results of randomized clinical trials and data from real clinical practice. The review discusses the literature data describing the condition of patients with atrial fibrillation while taking direct oral anticoagulants, according to the search query “Atrial fibrillation, effectiveness and safety of rivaroxaban, warfarin, comorbidity, atrial fibrillation, efficacy and safety of rivaroxaban, warfarin, comorbid status” for the period from 2010 to 2020 in open sources PubMed and e-library, and a strategy for the comprehensive protection of patients with atrial fibrillation when using rivaroxaban is proposed for consideration.

show abstract

Section: мультипликативные эффекты и профилактическая стратегия ранне...unclassified

The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation

Zolotovskaya

Sabanova

Давыдкин

2021

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

show abstract

Atrial fibrillation and the gut microbiota: is there a link?

Zor’kina¹,

Skirdenko²,

Gorbenko³

et al. 2022

Profil. med.

View full text Add to dashboard Cite

Glycaemic control in comorbid patients: an important element of CVD progression prevention

Trukhan,

Davidov,

Shevchenko

2023

Medicinskij sovet

View full text Add to dashboard Cite

There is a clear and specific bidirectional relationship between diabetes mellitus and cardiovascular disease. It is known that cardiovascular disease in patients with diabetes occurs 2–5 times more often than in people without diabetes. CVD itself, and it is cardiovascular outcomes, are the main cause of death in patients with diabetes mellitus, both in men and women. In diabetes mellitus, there is a high risk of coronary heart disease, myocardial infarction, arterial hypertension, and acute cerebrovascular accident, and patients with diabetes may experience painless acute myocardial infarction associated with the presence of autonomic cardiac neuropathy. Much more often in diabetes mellitus there are various rhythm disturbances, including paroxysmal forms of atrial fibrillation, which increase the risk of death by 1.8–2 times. Currently, numerous international clinical studies have convincingly demonstrated that improved glycemic control causes a significant reduction in the risk of late macroand microvascular complications of diabetes mellitus. The concept of dysglycemia includes disorders of glycated hemoglobin (HbA1c), fasting glycemia, postprandial glycemia, hypoglycemia, and glycemic variability. Dysglycemia increases the risk of developing type 2 diabetes mellitus and cardiovascular diseases, and their poor prognosis. HbA1c is the “gold standard” for monitoring glycemic control, but this indicator does not provide complete information about daily and intraday changes in glucose levels. Variability (not level) of fasting glucose determines cardiovascular mortality in patients with type 2 diabetes mellitus. Achieving glucose stability may become an additional therapeutic goal for the management of this category of patients with diabetes mellitus, and low glycemic variability is currently assessed as an additional target. Algorithms of specialized medical care for patients with diabetes mellitus recommend that patients with type 2 diabetes mellitus carry out self-monitoring, depending on the type of treatment taken and the degree of carbohydrate metabolism compensation. An important aspect of the technical impact on the adherence of patients to self-control and treatment of diabetes mellitus is the availability of convenient communication between the patient and the doctor, in particular, the possibility of contact remotely via a computer and mobile phone. In conclusion, the possibilities of a new model of the Contour® glucometer line, the Contour® Plus One glucometer, are considered.

show abstract

Atrial Fibrillation and Diabetes Mellitus: the Control of Thromboembolic Risk

Cited by 5 publications

References 51 publications

The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation

The Role of Rivaroxaban in a Comprehensive Protection Strategy for Patients with Atrial Fibrillation

Atrial fibrillation and the gut microbiota: is there a link?

Glycaemic control in comorbid patients: an important element of CVD progression prevention

Contact Info

Product

Resources

About